Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography

Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking

Ohlsson, A., Lindgren, J. ‐., Wahlén, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.181 · Cited by 475 · see citing works

Pharmacology of Marihuana

Pertwee, R. G. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90080-x · Cited by 384 · see citing works

Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man

Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303 · see citing works

A comparison of the pharmacological activity in man of intravenously administered 1368-11368-11368-1, cannabinol, and cannabidiol

Perez‐Reyes, M., Timmons, M. C., Davis, K. H., & Wall, E. M. (1973) · Cellular and Molecular Life Sciences · doi:10.1007/bf01922823 · Cited by 161 · see citing works

Cannabidiol and cannabinol in man

Hollister, L. E. (1973) · Cellular and Molecular Life Sciences · doi:10.1007/bf01946311 · Cited by 121 · see citing works

Interactions in man of delta‐9‐tetrahydrocannabinol; II. Cannabinol and cannabidiol

Hollister, L. E., & Gillespie, H. K. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518180 · Cited by 84 · see citing works

Marihuana Biological Effects

(1979) · Elsevier eBooks · doi:10.1016/c2013-0-03122-2 · Cited by 69 · see citing works

Mass Spectrometry in Drug Metabolism

Frigerio, A., & Ghisalberti, E. L. (1977) · Springer eBooks · doi:10.1007/978-1-4613-4151-2 · Cited by 47 · see citing works

Cannabidiol and δ9-tetrahydrocannabinol metabolism

Borys, H. K., & Karler, R. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90472-6 · Cited by 23 · see citing works

CLINICAL STUDIES ON THE INTERACTION OF PSYCHOPHARMACOLOGIC AGENTS WITH MARIHUANA

Lemberger, L., Dalton, B., Martz, R. C., Rodda, B. E., & Forney, R. B. (1976) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1976.tb27933.x · Cited by 12 · see citing works

Detection and Quantification of Cannabinoids in Human Blood Plasma

Ohlsson, A., Lindgren, J. ‐., Leander, K., & Agurell, S. (1977) · Springer eBooks · doi:10.1007/978-1-4613-4151-2_28 · Cited by 2 · see citing works

Pharmacokinetics and Pharmacodynamics of Cannabinoids

Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,514 · see citing works

Human Cannabinoid Pharmacokinetics

Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102 · see citing works

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · see citing works

The pharmacokinetics and the pharmacodynamics of cannabinoids

Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724 · see citing works

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402 · see citing works

Effects of ipsapirone and cannabidiol on human experimental anxiety

Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364 · see citing works

Controlled clinical trial of cannabidiol in Huntington's disease

Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324 · see citing works

Effects of cannabidiol (CBD) on regional cerebral blood flow

Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works

Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy

Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 302 · see citing works

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298 · see citing works

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294 · see citing works

Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration

Ohlsson, A., Lindgren, J., Andersson, S. K., Agurell, S., Gillespie, H. K., & Hollister, L. E. (1986) · Journal of Mass Spectrometry · doi:10.1002/bms.1200130206 · Cited by 240 · see citing works

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation

Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222 · see citing works

How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review

Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 222 · see citing works

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241 · see citing works

Pharmacology of cannabinoids in the treatment of epilepsy

Gaston, T. E., & Friedman, D. J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.016 · Cited by 209 · see citing works

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206 · see citing works

Effects of cannabidiol in animal models predictive of antipsychotic activity

Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191 · see citing works

Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination

Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 192 · see citing works

Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of Δ9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract

Nadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E., & Stadelmann, A. M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000177223.19294.5c · Cited by 186 · see citing works

Pharmacology of cannabinoids.

Grotenhermen, F. (2004) · PubMed · Cited by 175 · see citing works

Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol

Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M. L., O'Carrol, C., Atakan, Z., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990617 · Cited by 163 · see citing works

Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition

Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.011 · Cited by 195 · see citing works

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle

González‐Cuevas, G., Martin‐Fardon, R., Kerr, T. M., Stouffer, D. G., Parsons, L. H., Hammell, D. C., Banks, S. L., Stinchcomb, A. L., & Weiss, F. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0050-8 · Cited by 157 · see citing works

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

Schier, A. R. D. M., Ribeiro, N. P. D. O., Silva, A. C. D. O. E., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462012000500008 · Cited by 154 · see citing works

Cannabidiol reduces ethanol consumption, motivation and relapse in mice

Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 152 · see citing works

Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract

Nadulski, T., Sporkert, F., Schnelle, M., Stadelmann, A. M., Roser, P., Schefter, T., & Pragst, F. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.782 · Cited by 146 · see citing works

Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study

Winton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Martin-Santos, R., Ffytche, D., Zuardi, A. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.17 · Cited by 146 · see citing works

Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products

Anderson, G. D., & Chan, L. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0400-9 · Cited by 141 · see citing works

Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol

Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works

Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer

Kis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148 · see citing works

Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers

Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S., & Stinchcomb, A. L. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639041003657295 · Cited by 134 · see citing works

Endocannabinoids in nervous system health and disease: the big picture in a nutshell

Skaper, S. D., & Marzo, V. D. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0313 · Cited by 134 · see citing works

Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans

Manini, A. F., Yiannoulos, G., Bergamaschi, M. M., Hernandez, S. H., Olmedo, R., Barnes, A. J., Winkel, G. H., Sinha, R., Jutras‐Aswad, D., Huestis, M. A., et al. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000118 · Cited by 127 · see citing works

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

McAllister, S. D., Soroceanu, L., & Desprez, P. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9608-y · Cited by 139 · see citing works

Health consequences of acute and chronic marihuana use

Maykut, M. O. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90085-5 · Cited by 120 · see citing works

Review on clinical studies with cannabis and cannabinoids 2005-2009

Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 110 · see citing works

Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors

Jesus, C. H. A., Redivo, D. D. B., Gasparin, A. T., Sotomaior, B. B., de Carvalho, M. C., Genaro, K., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., Zanoveli, J. M., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.014 · Cited by 102 · see citing works

No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Linares, I. M. P., Guimarães, F. S., Éckeli, Á. L., Crippa, A. C. S., Zuardi, A. W., Souza, J. D. S., Hallak, J. E. C., & Crippa, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00315 · Cited by 99 · see citing works

The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation

Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165771 · Cited by 97 · see citing works

Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze

Guimarães, F. S., Aguiar, J. C. D., Mechoulam, R., & Breuer, A. (1994) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(94)90027-2 · Cited by 89 · see citing works

Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons

Straiker, A. J., Dvořáková, M., Zimmowitch, A., & Mackie, K. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.111864 · Cited by 86 · see citing works

Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans

Consroe, P. F., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90357-8 · Cited by 85 · see citing works

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

Turna, J., Syan, S. K., Frey, B. N., Rush, B. R., Costello, M. J., Weiss, M., & MacKillop, J. M. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13964 · Cited by 83 · see citing works

Cannabinoid therapy in epilepsy

Billakota, S., Devinsky, O., & Marsh, E. D. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000660 · Cited by 75 · see citing works

Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis

O’Neill, A., Wilson, R. P., Blest‐Hopley, G., Annibale, L., Colizzi, M., Brammer, M. J., Giampietro, V., & Bhattacharyya, S. (2020) · Psychological Medicine · doi:10.1017/s0033291719003519 · Cited by 75 · see citing works

The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations

Franco, V., Gershkovich, P., Perucca, E., & Bialer, M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00931-w · Cited by 76 · see citing works

Delivering therapeutic cannabinoids via skin: Current state and future perspectives

Tijani, A. O., Thakur, D., Mishra, D., Frempong, D., Chukwunyere, U. I., & Puri, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.005 · Cited by 66 · see citing works

Cannabidiol (CBD) Dosing: Plasma Pharmacokinetics and Effects on Accumulation in Skeletal Muscle, Liver and Adipose Tissue

Child, R. B., & Tallon, M. J. (2022) · Nutrients · doi:10.3390/nu14102101 · Cited by 65 · see citing works

Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder

Liput, D. J., Hammell, D. C., Stinchcomb, A. L., & Nixon, K. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.08.013 · Cited by 65 · see citing works

The Cannabinoids: An Overview. Therapeutic Implications in Vomiting and Nausea after Cancer Chemotherapy, in Appetite Promotion, in Multiple Sclerosis and in Neuroprotection

Mechoulam, R., & Hanus, L. O. (2001) · Pain Research and Management · doi:10.1155/2001/183057 · Cited by 60 · see citing works

Cannabis: Pharmacology and Interpretation of Effects

Mason, A., & McBay, A. J. (1985) · Journal of Forensic Sciences · doi:10.1520/jfs10998j · Cited by 58 · see citing works

Mass spectrometry of the cannabinoids and their metabolites

Harvey, D. J. (1987) · Mass Spectrometry Reviews · doi:10.1002/mas.1280060104 · Cited by 56 · see citing works

SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice

WILSON, D., Varvel, S. A., Harloe, J. P., Martin, B. R., & Lichtman, A. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.018 · Cited by 54 · see citing works

Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice

Karmaus, P. W. F., Wagner, J. G., Harkema, J. R., Kaminski, N. E., & Kaplan, B. L. F. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.741628 · Cited by 54 · see citing works

Clinical Pharmacokinetics of Cannabinoids

Grotenhermen, F. (2003) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n01_02 · Cited by 54 · see citing works

Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults

Arndt, D. L., & de Wit, H. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0014 · Cited by 54 · see citing works

Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative

da Silva, N. R., Gomes, F. V., Fonseca, M. M., Mechoulam, R., Breuer, A., Cunha, T. M., & Guimarães, F. S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.012 · Cited by 52 · see citing works

Cannabinoid treatments in epilepsy and seizure disorders

Devinsky, O., Jones, N. A., Cunningham, M. O., Jayasekera, B. A. P., Devore, S., & Whalley, B. J. (2023) · Physiological Reviews · doi:10.1152/physrev.00049.2021 · Cited by 52 · see citing works

Evaluation of pharmacokinetics and acute anti‐inflammatory potential of two oral cannabidiol preparations in healthy adults

Hobbs, J. M., Vazquez, A. R., Remijan, N. D., Trotter, R. E., Vincent, G. T., Freedman, K. E., Wei, Y., Woelfel, K. A., Arnold, O. R., Wolfe, L. M., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6651 · Cited by 46 · see citing works

Cannabinol and Sleep: Separating Fact from Fiction

Corroon, J. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0006 · Cited by 44 · see citing works

Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs

Polidoro, D. N., Temmerman, R., Devreese, M., Charalambous, M., Ham, L. V., Cornelis, I., Broeckx, B. J. G., Mandigers, P. J. J., Fischer, A., Storch, J., et al. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.899940 · Cited by 47 · see citing works

Kinetic study of smoking marijuana

Barnett, G., Chiang, C.-W. N., Perez‐Reyes, M., & Owens, S. M. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059033 · Cited by 44 · see citing works

The Skin and Natural Cannabinoids–Topical and Transdermal Applications

Filipiuc, S. I., Neagu, A.-N., Urîtu, C. M., Tamba, B.-I., Filipiuc, L.-E., Tudorancea, I. M., Boca, A. N., Hâncu, M. F., Porumb, V., & Bild, W. (2023) · Pharmaceuticals · doi:10.3390/ph16071049 · Cited by 42 · see citing works

Cannabimimetic activity of cannabinol in rats and pigeons

Järbe, T. U. C., & Hiltunen, A. J. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90212-7 · Cited by 41 · see citing works

Oral delivery of cannabidiol: Revealing the formulation and absorption challenges

Šitovs, A., Logviss, K., Lauberte, L., & Mohylyuk, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105316 · Cited by 40 · see citing works

Absorption, Distribution, and Biotransformation of the Cannabinoids

Harvey, D. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-710-9_10 · Cited by 39 · see citing works

Decarbonylation: A metabolic pathway of cannabidiol in humans

Krämer, M., Broecker, S., Madea, B., & Heß, C. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2572 · Cited by 38 · see citing works

Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos

Brigante, T. A. V., Abe, F. R., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & de Oliveira, D. P. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.06.008 · Cited by 37 · see citing works

Clinical Pharmacodynamics of Cannabinoids

Grotenhermen, F. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v04n01_03 · Cited by 38 · see citing works

Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking

Johansson, E., Ohlsson, A., Lindgren, J., Agurell, S., Gillespie, H. K., & Hollister, L. E. (1987) · Journal of Mass Spectrometry · doi:10.1002/bms.1200140904 · Cited by 35 · see citing works

Interactions between Δ9-tetrahydrocannabinol and cannabidiol as evaluated by drug discrimination procedures in rats and pigeons☆

Hiltunen, A. J., & Järbe, T. U. C. (1986) · Neuropharmacology · doi:10.1016/0028-3908(86)90034-1 · Cited by 33 · see citing works

SINGLE DOSE KINETICS OF CANNABIDIOL IN MAN

Ohlsson, A., Lindgren, J. ‐., Andersson, S. K., Agurell, S., Gillespie, H. K., & Hollister, L. E. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-044620-9.50020-8 · Cited by 28 · see citing works

Medicinal Cannabis and Central Nervous System Disorders

Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 27 · see citing works

Cannabidiol as an immune modulator: A comprehensive review

Mujahid, K., Rasheed, M. S., Sabir, A., Nam, J., Ramzan, T., Ashraf, W., & Imran, I. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00005-7 · Cited by 31 · see citing works

Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants

Peters, E. N., Mosesova, I., MacNair, L., Vandrey, R. G., Land, M. H., Ware, M. A., Turcotte, C. L., & Bonn‐Miller, M. O. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab026 · Cited by 25 · see citing works

Health benefits, pharmacological properties, and metabolism of cannabinol: A comprehensive review

Khouchlaa, A., Khouri, S., Hajib, A., Zeouk, I., Amalich, S., Msairi, S., Menyiy, N. E., Raïs, C., Lahyaoui, M., Khalid, A., et al. (2024) · Industrial Crops and Products · doi:10.1016/j.indcrop.2024.118359 · Cited by 24 · see citing works

THC and CBD blood and brain concentrations following daily administration to adolescent primates

Withey, S. L., Bergman, J., Huestis, M. A., George, S. R., & Madras, B. K. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108129 · Cited by 23 · see citing works

Cannabidiol Produces Distinct U-Shaped Dose-Response Effects on Cocaine-Induced Conditioned Place Preference and Associated Recruitment of Prelimbic Neurons in Male Rats

Nedelescu, H., Wagner, G. E., Ness, G. L. D., Carroll, A. M., Kerr, T. M., Wang, J., Zhang, S., Chang, S. E., Than, A., Emerson, N. E., et al. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.06.014 · Cited by 22 · see citing works

Current Cannabidiol Safety: A Review

Singh, C., Rao, K., Yadav, N., Vashist, Y., Chugh, P., Bansal, N., & Minocha, N. (2022) · Current Drug Safety · doi:10.2174/1574886317666220902100511 · Cited by 22 · see citing works

Long-Term, Self-Dosing CBD Users: Indications, Dosage, and Self-Perceptions on General Health/Symptoms and Drug Use

Kaufmann, R., Bozer, A. L. H., Kube, A., & Aqua, K. A. (2023) · Medical Cannabis and Cannabinoids · doi:10.1159/000531666 · Cited by 19 · see citing works

Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation

Hermush, V., Mizrahi, N., Tal, B., & Ezra, R. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00294-8 · Cited by 18 · see citing works

Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap

Cleirec, G., Desmier, E., Lacatus, C., Lesgourgues, S., Braun, A., Peloso, C., & Obadia, C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.899221 · Cited by 18 · see citing works

Cannabinoids for Therapeutic Use

Grotenhermen, F. (2004) · American Journal of Drug Delivery · doi:10.2165/00137696-200402040-00003 · Cited by 18 · see citing works

Cannabidiol—A friend or a foe?

Tihăuan, B.-M., Onisei, T., Slootweg, W., Gună, D., Iliescu, C., & Chifiriuc, M. C. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107036 · Cited by 16 · see citing works

Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters

Crippa, J. A. S., Pereira, L. C., Pereira, L. C., Zimmermann, P. M. D. R., Brum, L., Rechia, L. M., Dias, I. C. D. S., Hallak, J. E. C., Campos, A. C., Guimarães, F. S., et al. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1684 · Cited by 16 · see citing works

A broader view on deriving a reference dose for THC traces in foods

Beitzke, B., & Pate, D. W. (2021) · Critical Reviews in Toxicology · doi:10.1080/10408444.2021.2008867 · Cited by 16 · see citing works

Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants

Peters, E. N., Mosesova, I., MacNair, L., Vandrey, R. G., Land, M. H., Ware, M. A., Turcotte, C. L., & Bonn‐Miller, M. O. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab035 · Cited by 16 · see citing works

Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of Δ1-tetrahydrocannabinol in the rabbit

Harvey, D. J., Leuschner, J., & Paton, W. D. M. (1982) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)81984-6 · Cited by 16 · see citing works

A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women

Saals, B. A. D. F., de Bie, T. H., Osmanoglou, E., van de Laar, T., Tuin, A. W., van Orten-Luiten, A. C. B., & Witkamp, R. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-87621-4 · Cited by 19 · see citing works

The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer’s Disease

Trojan, V., Landa, L., Šulcová, A., Slíva, J., & Hřib, R. (2023) · Biomolecules · doi:10.3390/biom13101446 · Cited by 14 · see citing works

Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors

Escobar-Espinal, D. M., Vivanco-Estela, A. N., Barros, N., Pereira, M. D. S., Guimarães, F. S., Bel, E. D., & Nascimento, G. C. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110996 · Cited by 13 · see citing works

Medical Cannabis for the Treatment of Inflammation

Namdar, D., & Koltai, H. (2018) · Natural Product Communications · doi:10.1177/1934578x1801300304 · Cited by 13 · see citing works

The two synthetic cannabinoid compounds 4′‐ F‐CBD and HU ‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes

Pereira, M. D. S., Santos, B. M., Giménez, R., Guimarães, F. S., Raisman‐Vozari, R., Bel, E. A. D., & Michel, P. P. (2023) · Glia · doi:10.1002/glia.24489 · Cited by 12 · see citing works

Motivating intention to take action on behalf of an out-group: implications for the use of advocacy messages in social marketing strategies

Summers, J., & Summers, J. (2017) · Journal of Marketing Management · doi:10.1080/0267257x.2017.1311933 · Cited by 11 · see citing works

Chromophoric Labeling of Cannabinoids with 4-Dimethylaminoazobenzene-4'-Sulfonyl Chloride

Maseda, C., Fukui, Y., Kimura, K., & Matsubara, K. (1983) · Journal of Forensic Sciences · doi:10.1520/jfs11599j · Cited by 10 · see citing works

The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial

Kirkland, A. E., Browning, B. D., Meredith, L. R., Robertson, E. J., Herring, C., Tomko, R. L., Gray, K. M., & Squeglia, L. M. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02141-z · Cited by 11 · see citing works

Interactions in man of delta‐9‐tetrahydrocannabinol; II. Cannabinol and cannabidiol

Hollister, L. E., & Gillespie, H. K. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518180 · Cited by 84 · see citing works

Does co-administration of cannabidiol (CBD) influence the plasma availability of delta-9-tetrahydrocannabinol (THC) and its active metabolite in humans? A systematic review and meta-analysis

Chester, L. A., Sharafi, H., Mahroug, A., Ziegler, D., Hébert, F.-O., & Jutras‐Aswad, D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106910 · Cited by 1 · see citing works

Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC

Hložek, T., Uttl, L., Kadeřábek, L., Balı́ková, M., Lhotková, E., Horsley, R. R., Nováková, P., Šíchová, K., Štefková, K., Tylš, F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.10.037 · Cited by 235 · see citing works

Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract

Nadulski, T., Sporkert, F., Schnelle, M., Stadelmann, A. M., Roser, P., Schefter, T., & Pragst, F. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.782 · Cited by 146 · see citing works

A metabolic interaction in vivo between cannabidiol and Δ1‐tetrahydrocannabinol

Jones, G., & Pertwee, R. G. (1972) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1972.tb08092.x · Cited by 96 · see citing works